Description
Book SynopsisPart 1 : Lipoprotein Metabolism, Qualitative Changes and Measurements.- 1. Laboratory Assessment of Lipoproteins in Type 2 Diabetes.- 2. Tools for Assessing Lipoprotein Metabolism in Diabetes Mellitus.- 3. Links Between Glucose and Lipoproteins.- 4. Apoproteins and Cell Surface Receptors Regulating Lipoprotein Metabolism in the Setting of Type 2 Diabetes.- 5. Lipoprotein metabolism and alterations induced by insulin resistance and diabetes.- 6. The PPAR system in diabetes.- 7. Production And Metabolism Of Triglyceride-Rich Lipoproteins: Impact Of Diabetes.- 8. Triglyceride- And Cholesterol-Rich Remnant Lipoproteins In Risk Of Cardiovascular Disease In Diabetes Mellitus.- 9. HDL Function In Diabetes.- 10. Lipoprotein (a): Metabolism, Pathophysiology and Impact on Diabetes Mellitus.- 11. Lipoprotein Glycation in Diabetes Mellitus.- 12. Lipid:Extracellular Matrix Interactions as Therapeutic Targets in the Atherosclerosis of Diabetes.- Part 2 : Lipoproteins and the Complications of Diabetes.- 13. The Role of Modified Forms of LDL and Corresponding Autoantibodies in the Development of Complications in Diabetes.- 14. Endothelial dysfunction in type 2 diabetes, with an update on new interventions.- 15. Lipoproteins and diabetic kidney disease.- 16. Lipids and Diabetic Retinopathy.- 17. Roles of Extravasated and Modified Plasma Lipoproteins in Diabetic Retinopathy.- 18. The Role Of Lipids And Lipoproteins In Peripheral Neuropathy.- 19. Lipoproteins and Ischemic Stroke in Diabetes.- Part 3 : Lipoprotein Treatment in Diabetes.- 20. About Randomized Clinical Trials Related to Lipoproteins in Diabetes Mellitus.- 21. Effects of Lifestyle (Diet, Plant Sterols, Exercise and Smoking) and Glycemic Control on Lipoproteins in Diabetes.- 22. Statin Therapy: Impact on Dyslipidemia and Cardiovascular Events in Patients with Diabetes.- 23. Statin intolerance An overview for clinicians.- 24. Fibrate Therapy: Impact on Dyslipidemia and Cardiovascular Events in Patients with Diabetes Mellitus Type 2.- 25. EPA and Mixed Omega-3 Fatty Acids: Impact on Dyslipidemia and Cardiovascular Events in Patients With Diabetes.- 26. Cholesterol Absorption Inhibitors (Ezetimibe) and Bile Acid Binding Resins (Colesevelam HCl) as Therapy for Dyslipidemia in Patients with Diabetes Mellitus.- 27. Clinical Efficacy Of Proprotein Convertase Synthase Kexin Type 9 Inhibition In Persons With Diabetes Mellitus.- 28. Clinical Care of Lipids in People with Type 1 diabetes.- 29. Adjunct drug treatment to reduce vascular disease in people with diabetes.- 30. Emerging lipoprotein-related therapeutics for patients with diabetes.- Part 4 : Epidemiology of Diabetes and Diabetic Dyslipidemia.- 31. Diabetes Epidemiology And Its Implications.- 32. Epidemiology, Control, and Cardiovascular Outcomes of Dyslipidemia in Diabetes.
